Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CT 041

Drug Profile

CT 041

Alternative Names: 1-3 CT041 autologous CAR T-cell injection infusion; Anti-Claudin18.2-CAR-T cell therapy - CARsgen; CAR-CLD18 T cell therapy - CARsgen; CAR-CLDN18.2 T-Cells; Chimeric Antigen Receptor T cells targeting Claudin18.2; Claudin 18.2-CAR-T cell therapy - CARsgen; Claudin18.2 (CLDN18.2) CAR-T - CARsgen; Claudin18.2-redirected Autologous Cells - CARsgen; CLD18-CAR-T cell therapy - CARsgen; CLDN18.2 targeting CAR-T cell therapy - CARsgen; CT-041; CT041 autologous CAR T-cell injection

Latest Information Update: 23 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CARsgen
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Oesophageal cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer; Pancreatic cancer

Most Recent Events

  • 18 Jan 2024 Updated efficacy and adverse events data from a phase Ib/II trial in Pancreatic cancer and Gastric cancer presented at Gastrointestinal Cancers Symposium 2024 (ASCO-GCS-2024)
  • 21 Aug 2023 CARsgen and Moderna Therapeutics enters into a collaboration agreement to investigate CT 041 in combination with Moderna's mRNA cancer vaccine
  • 11 Jul 2023 Phase-I clinical trials in Pancreatic cancer (Adjuvant therapy) in China (IV) (NCT05911217)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top